0001209191-19-031868.txt : 20190521
0001209191-19-031868.hdr.sgml : 20190521
20190521201438
ACCESSION NUMBER: 0001209191-19-031868
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190517
FILED AS OF DATE: 20190521
DATE AS OF CHANGE: 20190521
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: STACK DAVID M
CENTRAL INDEX KEY: 0001204788
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21392
FILM NUMBER: 19843800
MAIL ADDRESS:
STREET 1: THE MEDICINES CO
STREET 2: 8 CAMPUS DRIVE
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMARIN CORP PLC\UK
CENTRAL INDEX KEY: 0000897448
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL,
STREET 2: SHELBOURNE ROAD, BALLSBRIDGE
CITY: DUBLIN
STATE: L2
ZIP: 00000
BUSINESS PHONE: 353 1 6699 020
MAIL ADDRESS:
STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL,
STREET 2: SHELBOURNE ROAD, BALLSBRIDGE
CITY: DUBLIN
STATE: L2
ZIP: 00000
FORMER COMPANY:
FORMER CONFORMED NAME: AMARIN PHARMACEUTICALS PLC
DATE OF NAME CHANGE: 20000201
FORMER COMPANY:
FORMER CONFORMED NAME: ETHICAL HOLDINGS PLC
DATE OF NAME CHANGE: 19930322
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-17
0
0000897448
AMARIN CORP PLC\UK
AMRN
0001204788
STACK DAVID M
C/O AMARIN PHARMA, INC.
1430 ROUTE 206
BEDMINSTER
NJ
07921
1
0
0
0
Ordinary Shares
2019-05-17
4
M
0
13174
3.21
A
13174
D
Ordinary Shares
2019-05-17
4
S
0
13174
18.0005
D
0
D
Stock Option (Right to Buy)
3.21
2019-05-17
4
M
0
13174
0.00
D
2028-05-14
Ordinary Shares
13174
33799
D
Stock Option (Right to Buy)
16.83
2019-05-20
4
A
0
9658
0.00
A
2029-05-20
Ordinary Shares
9658
9658
D
Restricted Stock Units
0.00
2019-05-20
4
A
0
7428
0.00
A
Ordinary Shares
7428
7428
D
The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Please see the section titled "Remarks" below for additional information.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The stock option granted to the Reporting Person is fully vested as of the date hereof.
On May 20, 2019, the Reporting Person was granted an option to purchase 9,658 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in 2020.
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer.
On May 20, 2019, the Reporting Person was granted 7,428 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in such year.
Not applicable.
In the case of a Change of Control (as defined in the Plan), the grants described in this Form 4 vest in full. This number does not represent the aggregate number of Ordinary Shares of the Issuer this Reporting Person holds or has a right to acquire in the form of stock options and restricted stock units granted to such Reporting Person. The grants made on May 20, 2019 are made in accordance with the Issuer's previously disclosed non-employee director compensation program.
/s/ Joseph Kennedy, by power of attorney
2019-05-21